Press Releases – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Wed, 02 Jan 2019 18:40:59 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.3 Creso Pharma’s Plans Progress as Israel’s New Medical Cannabis Export Law Passed by Parliament https://mjshareholders.com/creso-pharmas-plans-progress-as-israels-new-medical-cannabis-export-law-passed-by-parliament/ Wed, 02 Jan 2019 18:40:59 +0000 http://www.cannabisfn.com/?p=2151144

Ryan Allway

January 2nd, 2019

News, Press Releases


  • Israel’s Parliament approves law for exporting medicinal cannabis as well as a new
    regulatory structure to approve foreign ownership of Israeli medicinal cannabis operations
  • Creso is well positioned to take advantage of these changes via its 74% stake in a Joint
    Venture with Israeli-based Cohen Propagation Nurseries Ltd (“Cohen”)
  • This brings to life Creso’s plan to grow and export medical grade cannabis from Israel
  • Israel’s human capital, research know-how, exceptional skill base and start up mentality
    underpins enormous opportunities in this field.

Creso Pharma Limited (ASX: “CPH”, the “Company” or “Creso”) is pleased to announce its
strategic plan is a step closer with the Israeli Parliament’s approval to allow the export of medicinal cannabis from Israel. The new law will allow Israel to participate in the global medicinal cannabis industry once it receives Israeli Cabinet sign off.

Creso is well positioned to take advantage of these changes via its 74% stake in a Joint Venture
with Israeli-based Cohen nurseries. The JV will enable Creso to supply cannabis strains previously unavailable from Israeli cannabis producers.

Creso is one of few ASX traded company with operations in Israel and one of only a few Licensed Producers in Canada with access to Israeli strains. Recently Dr Sanjay Gupta, Chief Medical Correspondent for the Health, Medical and Wellness unit at CNN1 stated: “Israel is the marijuana research capital of the world.” Israeli Agriculture Minister Uri Ariel said: “The Israeli research conditions for growth in the field precede most of the countries in the world by five to seven years because of progressive regulation.”2

According to Michael Dor, Senior Medical Adviser at the Ministry of Health’s Medical Cannabis
Unit, “Right now, there are more than one hundred and ten clinical trials involving cannabis
underway in Israel, more than any other country. Many of those studies are funded by the Israeli government.” 2

This wealth of clinical research has resulted in the development of strains designed to treat specific ailments backed by hard research data, which is missing in most medicinal cannabis product claims. Dr. Miri Halperin Wernli, Creso’s CEO and Co-Founder has welcomed the new law and supports Israel joining the leading global export nations of medical cannabis. Said Dr Halperin Wernli: “Creso plans to access these exciting new proprietary Israeli strains which can also now be exported, either as whole plant or raw genetics to our own internal operations or to external licensed producers. “The legislation removes the last legal obstacle for medicinal cannabis exports and we look forward to taking advantage of Israel’s cutting edge technology and access to high-quality, well researched medicinal cannabis. “As a vertically integrated cannabis company with CBD products already commercialised and cannabis cultivation soon to start production in Canada as well as Colombia and Israel, Creso’s strategy is rapidly coming together to form a powerful enterprise actively participating in the global cannabis market which is projected to reach $60 billion by 2024.”

Creso is becoming an increasingly bigger global participant in the human and animal CBD
supplement market which is expected to exceed $350 billion by 2024. 3

Founded in 1958, Cohen is one of the most experienced agricultural companies in Israel and hassignificant operational know-how and proven capabilities in establishing high scale production greenhouses to international standards. Cohen owns and operates farms across south and central Israel with a total greenhouse capacity of 15.7 hectares / 38.7 acres. Creso conservatively estimates annual production of up to 2,500 kilograms of high-quality cannabis
per year from Cohen once the facility is at full capacity.

Licensed cannabis growers are expected to begin exporting medical cannabis products from Israel by mid-2019. Saul Kaye, CEO of iCAN recently stated: “The worldwide medical cannabis market is estimated to generate $33 billion dollars over the next five years with Israel expecting to rack up over $1 billion in export sales. Among the countries reportedly eager to trade with Israel include Australia, Germany, Austria and Mexico.” 4

In a country known to Wall Street as “Start-up Nation”, Israel is perfectly positioned to expose and take advantage of the growing opportunities in the sector. Importantly, Israel has the human capital, research know-how, skill base and start up mentality to excel and lead the field. With the new law passing Parliament the way is paved for cannabis to potentially become as important to Israel’s economy as technology.1

1 https://www.thegrowthop.com/cannabis-health/cannabis-medical/israeli-legislation-paves-the-way-for-exporting-medical-cannabis-in-
2019

2 https://mjbizdaily.com/israeli-parliament-approves-medical-cannabis-exports/

3 https://www.brightfieldgroup.com/post/hemp-cbd-market-to-reach-22-billion-by-2022-outpacing-the-rest-of-the-cannabis-market-
combined

4 https://www.forbes.com/sites/irisdorbian/2018/12/26/israeli-lawmakers-approve-law-to-export-medical-cannabis/#511bf3fb6806

Investor and Media Enquiries:
EverBlu Capital
Level 39, Aurora Place
88 Phillip Street, Sydney, NSW
2000
E: [email protected]

About Creso Pharma

www.cresopharma.com

Creso Pharma brings the best of cannabis to better the lives of people and animals. It brings
pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

About Cohen Propagation Nurseries Limited

Cohen Propagation Nurseries is a family business, established in 1958. Located in the centre of
Israel and spread over 3 different farms in Kfar Hanagid, Gderot and Nir Hen the company employs a 550 highly trained staff working across a total greenhouse area of 15.7 hectares.
Cohen’s products are famous for their high quality, sterility and hygiene and are supplied with a
special quality certificate from Israel’s Ministry of Agriculture Plant Protection and Inspection
Services. Cohen has been exporting cuttings for both bedding and basket plants since 1979.

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.
The cautionary statements qualify all forward-looking statements attributable to Creso and persons. acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Wiz Khalifa Partners with Supreme to Expand Cannabis Brand https://mjshareholders.com/wiz-khalifa-partners-with-supreme-to-expand-cannabis-brand/ Tue, 18 Dec 2018 18:45:46 +0000 http://www.cannabisfn.com/?p=2099403

Ryan Allway

December 18th, 2018

Exclusive, News, Press Releases, Top News


The music industry has become increasingly intertwined with the cannabis industry over the past several years. With the partnership between Canopy Growth Corp. (TSX: WEED) (NYSE: CGC) and Snoop Dogg in 2016, these relationships grew even closer on an international level. Cannabis companies around the world have sought out ways to partner with these musicians to leverage their cannabis expertise.

The Supreme Cannabis Company Inc. (TSX-V: FIRE) (OTCQX: SPRWF) (FRA: 53S1) recently announced an exclusive consulting agreement with Wiz Khalifa’s Khalifa Kush Enterprises (KKE) to develop and launch a line of premium cannabis products into the nascent Canadian market. The move could bring KKE’s tremendously successful strains in the United States market north of the border into Canada’s newly recreational market.

The Cannabis Tastemaker

Wiz Khalifa is a Grammy Award-winning American rapper, singer, songwriter, and actor that has become an icon within the cannabis community. After partnering with Colorado-based RiverRock Cannabis in 2016, Khalifa developed his own line of regulated marijuana strains, products, and concentrates under the Khalifa Kush brand. These products have already hit dispensary shelves across most states where cannabis has been legalized.

In addition to creating his own cannabis strains, the musician has taken other avenues to raise awareness for the cannabis industry. He launched Weed Farm on 4/20 last year—a mobile game where players can operate their own marijuana businesses—and continues to release albums, like Rolling Papers, that are cannabis-focused. He also continues to perform at cannabis cups and other industry events around the world.

The move follows many other high-profile celebrities that have introduced their own brands, including Snoop Dogg’s Leafs by Snoop, Bob Marley’s (heirs) Marley Naturals, Margaret Cho’s Cho-G, Willie Nelson’s Willie’s Reserve, and Tommy Chong’s Chong’s Choice. The popularity of these cannabis icons has made them extremely valuable to cannabis companies in the United States looking to expand consumer awareness.

Expansion into Canada

The Supreme Cannabis Company recently announced an exclusive consulting services agreement with Khalifa Kush Enterprises Canada ULC—an affiliate of Khalifa Kush Enterprises LLC in the United States. Under the terms of the agreement, the two companies will develop and launch a line of premium cannabis products under the KKE brand and distribute them through Canada’s nascent recreational market.

“Canada is a very important place to me with the idea for ‘Kush and Orange Juice’ being created in Toronto, it’s the perfect start for the international expansion of Khalifa Kush,” said Wiz Khalifa, Principal of KKE. “My team and I have spent the past year finding a partner that shares our vision, values, and passion for cannabis. The team at Supreme Cannabis understands the importance of high quality cannabis and how to produce [it at scale].”

Supreme Cannabis will have exclusive rights to the KKE brand within Canada, as well as potential expansion into international markets, pending approval from KKE and the legal status of the products in those markets. While celebrity endorsements aren’t permitted by Health Canada, the KKE brand’s strong reputation in the United States could help reassure customers of the ultra-premium quality of the cannabis.

“Wiz is a globally-recognized cannabis taste maker and connoisseur,” said Supreme Cannabis President John Fowler. “I was impressed by the quality of the ‘Khalifa Kush’ strain and the level of care and involvement Wiz had with developing the strain and working with cultivators to continue to improve quality batch-by-batch. We’re excited to be working with KKE Canada to build out another brand with the same commitment to quality.”

Looking Ahead

The Supreme Cannabis Company Inc. (TSX-V: FIRE) (OTCQX: SPRWF) (FRA: 53S1) represents a compelling investment opportunity in Canada’s cannabis industry. In addition to its partnership with Wiz Khalifa, the company’s 7ACRES licensed producer subsidiary operates a 342,000 sq. ft. facility in Ontario that has already secured numerous provincial supply agreements and consistently ranks high among recreational brands.

The company’s portfolio also includes an equity investment and long-term global distribution partnership with Lesotho-based Medigrow for the exportation of medical-grade cannabis oil.

For more information, visit the company’s website at www.supreme.ca.

Disclaimer 

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
The Alkaline Water Company Commends Farm Bill Passage as Driver for Consumer Access to CBD-Infused Beverages https://mjshareholders.com/the-alkaline-water-company-commends-farm-bill-passage-as-driver-for-consumer-access-to-cbd-infused-beverages/ Fri, 14 Dec 2018 14:08:40 +0000 http://www.cannabisfn.com/?p=2074920

Ryan Allway

December 14th, 2018

Press Releases, Top News


SCOTTSDALE, Ariz., Dec. 13, 2018 (GLOBE NEWSWIRE) — The Alkaline Water Company Inc. (NASDAQ and TSXV: WTER) (the “Company”), with products bottled under the trademark Alkaline88®, announced today that, following the passage of the Agriculture Improvement Act of 2018 (Farm Bill), the Company is well-positioned to capitalize on the opportunity to be one of the first national U.S. beverage companies to bring the true water-soluble, full-spectrum features of bioactive cannabidiol (CBD) molecules from hemp plants to U.S. consumers through its A88 Infused Beverage Division, Inc. (A88 Infused).

“We are very excited that Congress has passed legislation redefining hemp to include extracts, cannabinoids and derivatives, which will permanently remove hemp from the Controlled Substances Act (CSA),” said Ricky Wright, President and CEO of The Alkaline Water Company. “This is a significant step forward for consumers who are looking to access CBD and CBD-infused products. As local and state legislatures, as well as the U.S. Food and Drug Administration (FDA), finalize their regulations for hemp, we are well-positioned to launch our great tasting Alkaline88® infused with natural hemp-extract formulations to become a dominant brand in this beverage category.”

A88 Infused’s recently announced agreement with Infusion Biosciences, Inc. (IBS) will enable the Company to combine its state-of-the-art Electrochemically Activated Water (ECA) system with IBS’ Aqueous Phytorecovery Process (APP) technology and leverage these proprietary formulations to infuse water-soluble cannabinoids without the use of any chemicals or additives. The merger of IBS’ science and technology with the power and integrity of the Alkaline88® brand is expected to create a market-leading approach to the fast-growing hemp-infused beverage category. All CBD-infused Alkaline88® water will be branded as SOOTHETM and will initially be available in the 500 ml size with a dosage of 8.8 mg of Hemp-extract per bottle. We anticipate these products will be on the market in the first quarter 2019.

A88 Infused’s new line of full spectrum hemp-extract beverages will include:

  • Hemp-Extract Alkaline88® Water (including grapefruit,  peach mango, raspberry, and lemon lime)
  • Sparkling Hemp-Extract Infused water (including grapefruit,  peach mango, raspberry, and lemon lime)

The Company fully intends to comply with all federal, state, and local laws, rules and regulations as the Company develops its hemp-infused alkaline water and other nutraceutical product lines. The Company will not pursue the production or sale of hemp-infused products until legally permitted and all necessary approvals have been obtained.

About The Alkaline Water Company Inc. 

The Alkaline Water Company Inc. (NASDAQ and TSXV: WTER) is a leading producer of premium bottled alkaline drinking water sold under the brand name Alkaline88®. With its innovative, state-of-the-art, proprietary electrolysis process, the Company produces healthy, all-natural and great-tasting alkaline water for a balanced lifestyle. Founded in 2012, the Company is headquartered in Scottsdale, Arizona, and focuses on national distribution and marketing for retail sale of Alkaline88®, one of the fastest growing premium bottled water brands on the market. To learn more about The Alkaline Water Company, please visit: www.thealkalinewaterco.com or connect on Facebook, Twitter, Instagram or LinkedIn.

About Alkaline Water Products
Alkaline88® is a premier 8.8 pH-balanced bottled alkaline drinking water, enhanced with Himalayan Pink Rock Salt, and the #1 selling bulk alkaline water in the United States. The product offers consumers the unique opportunity to purchase alkaline water in conveniently packaged 500-milliliter, 700-milliliter, 1-liter, 1.5-liter, 3-liter and 1-gallon sizes. Alkaline88® is available in over 47,500 retailers in all 50 states, including national retailers such as Safeway/Albertsons, Walmart, Kroger, CVS, and other top regional and local supermarket chains. To find a retailer near you visit: http://thealkalinewaterco.com/about-us/locations/

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements.”  Statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the following: that the Company is well-positioned to capitalize on the opportunity to be the first national U.S. beverage companies to bring the true water-soluble, full-spectrum features of bioactive cannabidiol (CBD) molecules from hemp plants to U.S. consumers through its A88 Infused; that the Company is well-positioned to launch its great tasting Alkaline88® infused with natural hemp-extract formulations to become a dominant brand in this beverage category; that A88 Infused’s recently announced agreement with IBS will enable the company to combine its state-of-the-art ECA system with IBS’ APP technology and leverage these proprietary formulations to infuse water-soluble cannabinoids without the use of any chemicals or additives; that the merger of IBS’ science and technology with the power and integrity of the Alkaline88® brand is expected to create a market-leading approach to the fast-growing hemp-infused beverage category; that all CBD-infused Alkaline88®water will be branded as SOOTHETM and will initially be available in the 500 ml size with a dosage of 8.8 mg of Hemp-extract per bottle and the Company anticipates these products will be on the market in the first quarter 2019; and that A88 Infused’s new line of full spectrum hemp-extract beverages will include Hemp-Extract Alkaline88® Water (including grapefruit, coconut, peach mango, raspberry, and lemon lime) and Sparkling Hemp-Extract Infused water (including grapefruit, coconut, peach mango, raspberry, and lemon lime).

The material assumptions supporting these forward-looking statements include, among others, that the demand for the Company’s products will continue to significantly grow; that the past production capacity of the Company’s co-packing facilities can be maintained or increased; that the Company will receive all necessary regulatory approvals for the production and sale of CBD/hemp-infused water that there will be increased production capacity through implementation of new production facilities, new co-packers and new technology; that there will be an increase in number of products available for sale to retailers and consumers; that there will be an expansion in geographical areas by national retailers carrying the Company’s products; that there will be an expansion into new national and regional grocery retailers; that there will not be interruptions on production of the Company’s products; that there will not be a recall of products due to unintended contamination or other adverse events relating to the Company’s products; and that the Company will be able to obtain additional capital to meet the Company’s growing demand and satisfy the capital expenditure requirements needed to increase production and support sales activity. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, governmental regulations being implemented regarding the production and sale of alkaline water or any other products, including products containing CBD/hemp; the fact that consumers may not embrace and purchase any of the Company’s infused water products; the fact that the Company may not receive approval for any of its CBD infused products; the fact that even though the Farm Bill was passed into law, the Company may not receive approval from state and local regulatory bodies, the US Drug Association or the FDA for its CBD/hemp-infused products; additional competitors selling alkaline water and enhanced water products in bulk containers reducing the Company’s sales; the fact that the Company does not own or operate any of its production facilities and that co-packers may not renew current agreements and/or not satisfy increased production quotas; that fact that the Company has a limited number of suppliers of its unique bulk bottles; the potential for supply chain interruption due to factors beyond the Company’s control; the fact that there may be a recall of products due to unintended contamination; the inherent uncertainties associated with operating as an early stage company; changes in customer demand and the fact consumers may not embrace enhanced water products as expected or at all; the extent to which the Company is successful in gaining new long-term relationships with new retailers and retaining existing relationships with retailers; the Company’s ability to raise the additional funding that it will need to continue to pursue its business, planned capital expansion and sales activity; competition in the industry in which the Company operates and market conditions. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States and Canada. Although the Company believes that any beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Readers should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents the Company files with the SEC, available at www.sec.gov, and on the SEDAR, available at www.sedar.com.

The Alkaline Water Company Inc.

Richard A. Wright
President and CEO
480-656-2423
investors@thealkalinewaterco.com

Media
Elizabeth Van Every
Burson Cohn & Wolfe
212-614-3881
Elizabeth.vanevery@bcw-global.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/554bc0fc-d7af-44f0-8d0b-e55777d23a80

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Biome Receives DTC Eligibility https://mjshareholders.com/biome-receives-dtc-eligibility/ Fri, 14 Dec 2018 14:06:43 +0000 http://www.cannabisfn.com/?p=2076942

Ryan Allway

December 14th, 2018

Press Releases, Top News


December 13, 2018 – Toronto, ON – Biome Grow Inc. (“Biome” or the “Company”) (CSE: BIO) (OTC: ORTFF) (FSE: 60TA) announces that it has secured The Depository Trust Company (“DTC”) eligibility for its shares traded in the United States under the symbol ORTFF. The Company’s common shares traded on the OTC Market in the United States, under the symbol “ORTFF” are DTC eligible, effective December 13th, 2018. The “DTC” will facilitate electronic settlement of transfers of its common shares in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for certain investors.

Khurram Malik, Chief Executive Officer of Biome states: “We are very pleased to have obtained DTC eligibility. Biome is registering its shares with DTC as a fundamental step towards establishing the company with the American investment community. This electronic method of clearing securities expedites the receipt of stock and cash, and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms. The DTC’s electronic settlement of our shares is critical to having an effective market.”

The “DTC” is a subsidiary of the Depository Trust & Clearing Corp. that manages the electronic clearing and settlement of publicly traded companies in the United States.  DTC eligibility will simplify the process of trading and is expected to enhance liquidity of the Company’s common shares on the OTC marketplace.

About Biome  

Biome wholly owns five subsidiaries, including: The Back Home Medical CannabisCorporation, a company incorporated under the laws of the Province ofNewfoundland and Labrador and in the late stages of applying for a license under the ACMPR; Great Lakes Cannabis, a company incorporated under the laws of the Province of Ontario and in the late stages of applying for a license under the ACMPR; Highland Grow Inc., a licensed producer in Nova Scotia underCanada’s ACMPR; Red Sands Craft Cannabis Co., a company incorporated under the laws of the Province of Prince Edward Island, and; Weed Virtual Retail Inc., a company incorporated under the laws of the Province of Ontario in the business of operating a new virtual reality technology platform focused exclusively on the medical and recreational cannabis markets. Biome is a Canadian-based company with national and international business interests.

Forward-looking Statements

This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “proposed”, “is expected”, “budgets”,“scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward‐looking statements and information concerningDTC eligibility and the process associated with shares trading in the UnitedStates under this methodSuch forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to Biome with respect to DTC eligibility and electronic settlement of transfers in the United States.

These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements speak only as of the date on which they are made, and Biome, or any of its subsidiaries undertakes no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

For further information:

Khurram Malik,

Chief ExecutiveOfficer, Biome Grow

(416)-875-8395

info@biomegrow.com

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
48North Cannabis Corp. Acquires Good & Green for Next Generation Cannabis Products https://mjshareholders.com/48north-cannabis-corp-acquires-good-green-for-next-generation-cannabis-products/ Thu, 08 Nov 2018 14:38:56 +0000 http://www.cannabisfn.com/?p=1864029

Ryan Allway

November 8th, 2018

Exclusive, News, Press Releases, Top News


In late October of this 2018, 48North Cannabis Corp. (TSX-V: NRTH) entered into a binding letter agreement to acquire all issued and outstanding common shares of privately-held Good & Green, a socially-responsible, organic cannabis brand. Combined with a variety of vertically integrated partnerships, investors are keen to watch the movement of 48North as it takes command as a leader in both cannabis manufacturing and consumer packaged goods.

Good & Green

The acquisition provides an additional 46,000 square feet of licensed indoor cultivation and manufacturing facility, situated on five-acres of land in Brantford, Ontario. This site has an initial production area of 14,000 square feet and another 25,500 square feet will be immediately available for additional indoor cultivation. The site will also create a laboratory designed for pre and post-production that will precipitate large-scale extraction and next-generation product, research, and development. The Brantford indoor facility is expected to produce 2,500 kilograms of dried cannabis in 2019.

This significant production footprint will add to 48North’s existing licensed facility in Kirkland Lake, Ontario, and projects the Brantford-area farm to boost production to an expected 40,000 kilograms of sun-grown cannabis in 2019.

Good & Green’s senior team, including Jeannette VanderMarel and Daniel Goldberg, have been involved in the MMPR/ACMPR/Cannabis Act since its inception. Together they have 12-plus years of experience and have developed over a million square feet of federally licensed cannabis cultivation space.

Goldberg, co-founder and current CEO of Good & Green, is pleased to be combining forces with 48North, a company that he says “shares our commitment to the highest environmental, social and governance standards, to developing high-quality and consistent products and to achieving best-in-class financial performance.”

VanderMarel, co-founder and President of Good & Green who was a co-founder as well of The Green Organic Dutchman (TGOD), is just as enthusiastic: “48North continues to be a leader in developing cannabis brands and products with a future-focus that looks beyond flower and oil. We look forward to adding our expertise and significant low-cost organic production profile to further develop this dynamic and innovative vertically-integrated cannabis company.”

After closing of the acquisition, set for late November, VanderMarel will join the Board of Directors of 48North and become co-CEO. Goldberg, assigned as Senior Advisor, will focus on strategy, business and corporate development, strategic partnerships, communications, as well as investor and government relations for 48North.

MariPharm B.V.

48North’s assets also include a license by Health Canada for cultivation, sales, and extraction of cannabis by using unique genetics sourced from MariPharm B.V. As holder of the first cannabis cultivation license in the Netherlands and as member of the International Cannabinoid Research Council for 20 years, Maripharm B.V. has been researching the application and effects of medical cannabis in partnership with governments and universities for over 25 years. With a large-scale, sun-grown 100-acre outdoor farm, MariPharm B.V. brings expertise and experience to 48North by creating compliant, consistent, and distinctive CBD and THC products.

48North’s Growing Portfolio

Currently 48North has a growing portfolio of brands that include Latitude, a women’s cannabis platform; DelShen Therapeutics Corp., the company’s existing wholly-owned Licensed Producer; and Mother & Clone, producers of a rapid-acting sublingual cannabis nanospray.

The opportunity to leverage a combined portfolio of authentic, socially responsible, high-quality cannabis brands, along with the diversity and range of brands, will increase access to multiple demographic segments through complimentary values-driven brands.

Playing By The Numbers

48North Cannabis Corp targets production cost at $0.25 per gram, a cost basis that is currently a fraction of the lowest-cost producer.

With strong access to immediately available capital, the concurrent financing from this acquisition provides liquidity to support the continued expansion of both companies (including the development of Good & Green’s 100-acre farm). The anticipated large-scale extraction capabilities should significantly increase 2019 production and facilitate the rapid development of innovative, next-generation cannabis products.

Looking Forward

48North Cannabis Corp. (TSX-V: NRTH) cultivates premium cannabis products for the health and wellness market. The company partners with leading consumer-packaged companies in the food, beverage, cosmetic, and skincare market. By leveraging a well-arranged supply chain, 48North is prepared to take a commanding lead in the formulation, production, and distribution of next generation cannabis-infused products.

As a future-focused cannabis company, 48North’s objective addresses female-driven health and wellness issues, but also looks to serve future advancements in the cannabis industry through the development and manufacturing of proprietary products and brands for a variety of consumers.

Please click here to see the company’s Investor Kit.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
CFN Media’s Exclusive Interview with Pascal Biosciences https://mjshareholders.com/cfn-medias-exclusive-interview-with-pascal-biosciences/ Thu, 08 Nov 2018 14:30:14 +0000 http://www.cannabisfn.com/?p=1866397

Ryan Allway

November 8th, 2018

Exclusive, News, Press Releases, Top Story


The cannabis industry is projected to reach $75 billion by 2030, according to Cowen & Co., driven by the legalization of medical and recreational cannabis across a growing number of states. While many investors are familiar with cultivators and dispensaries, there could be an even greater opportunity on the medical side of the industry. Cannabinoids could displace blockbuster drugs, such as opioids, and provide breakthroughs in other areas.

CFN Media recently sat down with Pascal Biosciences Inc. (TSX-V: PAS) President & CEO Dr. Patrick W. Gray to discuss how the company is harnessing the power of cannabis to develop cancer therapeutics.

CFN Media: Your company hasn’t always been focused on cannabis. What led you to take a closer look at cannabis and discover the molecules that stimulate the immune system to destroy cancer cells?

Dr. Patrick W. Gray: “Our work at Pascal began with our sponsored research at the University of British Columbia. We have a proprietary method to search for compounds that can enhance the immune system, and a cannabinoid had the greatest activity. We have since analyzed nearly 400 cannabinoids–natural, synthetic, and endogenous—and we’ve identified even more potent structures that are currently being tested in preclinical immune-oncology studies. These discoveries about the anti-cancer effects of cannabinoids are novel and fit with Pascal’s goal to develop therapeutics for cancer.”

CFN Media: You recently announced the addition of a new cannabinoid program for the treatment of Glioblastoma. How does this program tie in to your immune surveillance program?

Dr. Patrick W. Gray: “I have known the inventor of this technology, Dr. Nephi Stella, for nearly ten years, and followed his work closely. When I saw his impressive results in a glioblastoma animal model, I was convinced this is a great program for Pascal. Glioblastoma is a terrible form of brain cancer, and I believe Dr. Stella’s cannabinoid-based product has great potential in treating this devastating disease. Furthermore, Dr. Stella will be a consultant for Pascal, and his 20 years of experience with cannabinoids will greatly aid our immune surveillance program. Dr. Stella has done pioneering research with cannabinoids, and he will bring that expertise to our programs.”

CFN Media: Is Pascal considering any partnerships for your cannabinoid programs?

Dr. Patrick W. Gray: “As you mentioned, there is great medical potential for cannabinoids, with a clear benefit for patients with pain, nausea, muscle spasms, epilepsy, and anxiety. However, most clinical studies are suggestive at best, and specific cannabinoids have generally not been associated with patient benefit. Our work is focused on identifying specific cannabinoids with potency for certain ailments. We believe our work will be of significant interest to potential partners, including both cannabis companies and pharmaceutical companies. The value of our programs will continue to increase as we progress, and we intend to engage potential partners when significant value is attained.”

CFN Media: You recently secured a DEA Schedule I license for cannabinoid development. Can you describe the process of securing that license and why it’s significant?

Dr. Patrick W. Gray: “Obtaining a DEA Schedule I license for Research was a critical step in further developing our immune surveillance program using cannabinoids. The process is quite rigorous. Yet, since we received our license, we have screened nearly 400 cannabis derived compounds, many of which are restricted, and have made significant progress in identifying therapeutic candidates.”

CFN Media: What are some of the key upcoming catalysts that shareholders can look forward to? Where do your clinical programs stand at this point in time?

Dr. Patrick W. Gray: “Our cannabinoid-based program for glioblastoma is expected to begin human clinical trials in 2019, a significant milestone for the company. In addition, our immune surveillance program is progressing nicely with some exciting discoveries. We will report our advancements in the scientific literature, at international conferences, and in press releases. Investors can expect updates on our programs in a timely fashion, because we have a lot of exciting information to share!”

CFN Media: Why should investors consider your stock?

Dr. Patrick W. Gray: “Pascal has an exciting pipeline developing cannabinoid therapeutics for cancer. Cannabinoid-based medicines are a fast-growing opportunity given the legalization of cannabis in Canada. The current competitive landscape for biotechnology companies developing cannabinoid therapeutics is small with diverse indications. Pascal stands out as one of the few companies targeting glioblastoma and, more broadly, cancer in combination with checkpoint inhibitors. Our utmost priority is to help patients suffering from life-threatening diseases, and we strongly believe that our current portfolio can make an impact on patient lives.”

CFN Media: Thank you for taking the time to speak with us.

About Pascal Biosciences Inc.

Pascal Biosciences Inc. (TSX-V:PAS) is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The company’s leading cannabinoid portfolio comprises a small molecule therapeutic, ST-403, that is advancing into clinical trials for the treatment of glioblastoma, and an immuno-stimulatory molecule. In addition, Pascal Biosciences is developing a B-cell targeted antibody for acute lymphoblastic leukemia and an antibody for calcium channels expressed by the immune system. For more information, visit www.pascalbiosciences.com.

To learn more, visit: https://www.pascalbiosciences.com/.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Pascal Biosciences Announces Optimization of Cannabinoid-Derived Drug Candidates to Kill Glioblastoma Cells https://mjshareholders.com/pascal-biosciences-announces-optimization-of-cannabinoid-derived-drug-candidates-to-kill-glioblastoma-cells/ Mon, 05 Nov 2018 16:42:49 +0000 http://www.cannabisfn.com/?p=1851404

Ryan Allway

November 5th, 2018

News, Press Releases


VANCOUVER, British Columbia and SEATTLE, Nov. 05, 2018 (GLOBE NEWSWIRE) — Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the peer reviewed publication and upcoming presentation of their recently licensed cannabinoid-derived drug program for glioblastoma. Dr. Stella and colleagues are publishing their work today in the European Journal of Medicinal Chemistry(Vol.159), a peer reviewed journal with a high impact value. These results will be presented at the 23rd Annual Meeting of the Society for Neuro-Oncology in New Orleans, on Saturday, November 17, 2018 (Poster # DDIS-12).

The findings, titled: “Modified carbazoles destabilize microtubules and kill glioblastoma multiform cells,” summarize research headed by Dr. Nephi Stella, founder and co-director of the University of Washington Center for Cannabis Research. This work details the discovery of compounds based on cannabinoids, and follows their chemical optimization into potent tumor killing agents.

“Our compounds kill tumor cells derived from patients with glioblastoma,” said Dr. Stella. “I’m excited to see Pascal rapidly advancing this promising program, as it has great potential to help patients diagnosed with glioblastoma, brain metastases and other devastating cancers.”

“This work is covered by intellectual property licensed by Pascal, resulting in the next generation of cannabinoid-based therapeutics for treating devastating brain cancers,” said Dr. Patrick Gray, CEO of Pascal. “We are eager to begin clinical trials for our first therapeutic next year, and Dr. Stella’s vast expertise will also advance our other cannabinoid programs.”
Pascal recently licensed the portfolio of cannabinoids and related compounds synthesized by Dr. Stella at the University of Washington and Dr. Philippe Diaz of the University of Montana. Pascal is advancing its lead candidate ST-403 into clinical trials, which are targeted to begin in 2019.

About ST-403 and Glioblastoma

ST-403 is a mitosis inhibitor that blocks cell division. Drugs of this class disrupt microtubules, which are the structures that pull chromosomes apart during cell division. There are several mitotic inhibitors approved for cancer treatment, including paclitaxel and vinblastine, and they have substantial benefit on solid tumors when combined with other chemotherapeutics. However, unlike ST-403, none of these agents cross the blood brain barrier and therefore have no activity on glioblastoma or other brain cancers.

Glioblastoma multiforme is a devastating disease for patients with limited treatment options due to the high rate of recurrence and aggressive tumor growth. According to the National Brain Tumor Society, glioblastoma strikes about 15,000 patients each year in North America with a median survival rate of 12 to 17 months. Therapies to treat glioblastoma are limited to surgery, radiation and chemotherapy, and more recently tumor treating fields. The only chemotherapeutic approved for glioblastoma is temozolomide, which was developed over 50 years ago and extends survival by only two months. Temozolomide kills tumor cells by causing DNA damage, a mechanism that is different from ST compounds. Temozolomide is now off patent protection, but previously had sales over $1B per year, so the commercial potential of ST-403 may be significant.

About Pascal Biosciences Inc. 

Pascal Biosciences is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The company’s leading cannabinoid portfolio comprises a small molecule therapeutic, ST-403, that is advancing into clinical trials for the treatment of glioblastoma, and an immuno-stimulatory molecule. In addition, Pascal Biosciences is developing a B-cell targeted antibody for acute lymphoblastic leukemia and an antibody for calcium channels expressed by the immune system. For more information, visit www.pascalbiosciences.com.

On Behalf of the Board of Directors
Dr. Patrick W. Gray, President &CEO

Investors:
invest@pascalbiosciences.com

Media Contact:
Julie Rathbun
Tel: 206-769-9219

DISCLAIMER
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”

pascallogo.jpg

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Gabriella’s Kitchen Confirms Its Cannabis-Infused alto™ Products Have Launched in Northern California https://mjshareholders.com/gabriellas-kitchen-confirms-its-cannabis-infused-alto-products-have-launched-in-northern-california/ Fri, 02 Nov 2018 17:12:29 +0000 http://www.cannabisfn.com/?p=1833789

GABY offers a variety of alto™ products including a line infused with cannabis-derived cannabinoids (including CBD and THC) which are part of GABY’s “better-for-you” edibles line, the first such line to be offered, representing an entirely new approach to cannabis-infused products. The initial alto™ products released consist of infused, flavored olive oils, including an extra virgin olive oil, a truffle-infused olive oil, and a garlic-infused olive oil. In addition to the flavour-infusion, all are further infused with CBD or with a combination of CBD and THC, with a dosage per bottle (8 servings per bottle) ranging from 20 mg to 72 mg of THC (2. 5 mg to 5 mg per serving) and 36 mg to 96 mg of CBD (4.5 mg to 4 mg per serving). For those wishing to enjoy alto™ without cannabinoids, GABY sells uninfused alto™ products on its website: www.gabriellas-kitchen.com

“We are extremely pleased to be adding the altoTM line into our product family,” states Aaron Browe, Chief Executive Officer at Sonoma Pacific Distribution, a distributor of cannabis products in California. “The needs of the cannabis consumer are evolving, and the altoTM brand is filling a much-needed gap in this market; Gabriella’s Kitchen is a trailblazer and we are excited to see the evolution and growth of this brand.”

GABY’s alto™ line represents an extension of the Company’s existing established portfolio of healthy and nutritional meals, sauces and other “better-for-you” products currently sold in over 3,400 mainstream retailers across the United States and Canada.  The alto™ products provide consumers with an innovative way to enhance their healthy living by supplementing every day ingredients with the health benefits offered by CBD and THC.  In addition to this initial offering of infused oils, GABY is in various stages of development of additional and further differentiated products that it plans to launch over the coming weeks and into early 2019.  The Company’s Infused Products are an ideal complement to the Aunt Zelda’s™ line of topicals, tinctures and concentrates, which was acquired by GABY through the acquisition of The Oil Plant (“TOP“), the closing of which was announced on October 16, 2018.

“We are very excited to see our altoTM products being shipped to California dispensaries, enabling customers to supplement their healthy living practices with delicious and nutritious options of infused cooking oils,” said Margot Micallef, Founder and CEO of Gabriella’s Kitchen.  “We are particularly pleased that alto™ was introduced to the market by our very own distribution company, Sonoma Pacific Distribution, following the announcement of the acquisition of that company only last week”.

GABY’s growth strategy is centered around creating value for both consumers and investors by filling the void that exists between the medical and recreational cannabis markets and serves to position the Company well to leverage its early mover advantage in the developing cannabis wellness market.  Through a combination of both acquisitions and organic growth, GABY intends to continue creating long-term shareholder value.  The accretive value of the Company’s acquisition strategy is evidenced by how quickly GABY was able to leverage the Sonoma Pacific Distribution transaction into potential revenue through the distribution of its altoTM products into the California market, which is expected to be followed by expansion into other potential markets in the future.

About Gabriella’s Kitchen

Gabriella’s Kitchen (GABY) is a pure-play cannabis wellness company holding a manufacturing and a distribution license issued by the California Bureau of Cannabis Control.  With these licenses and with its existing infrastructure of major retailers and an extensive broker and distribution network, GABY is positioned to service both mainstream grocery with CBD infused products, and licensed cannabis retailers with CBD and THC-infused products throughout Canada and the United States. The Company’s also has over 25 non-infused products available in more than 3,400 major retail stores across the U.S. and Canada.

Italian sisters Margot and Gabriella co-founded GABY to bring high quality, delicious, healthy superfoods to the market. The desire to create the all-encompassing wellness company came after Gabriella received a dire cancer diagnosis which spurred the sisters to prolong Gabriella’s life through a holistic approach to health. GABY directly and through TOP now offers a diverse range of products that cater to a variety of dietary and health concerns. Although Gabriella ultimately passed away from her illness, she lived exponentially longer and had better quality of life than doctors predicted. Her memory and passion live on through GABY’s mission: to empower people to live healthy lives without compromise.

Disclaimer and Forward-Looking Information

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release. Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, certain of which are beyond the control of Gabriella’s Kitchen Inc. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward looking statements include, but are not limited to, the anticipated availability of the Company’s Infused Products. The Company assumes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

The Oil Plant, Inc. (“TOP“) is a wholly owned subsidiary of GABY. TOP owns cannabis license in California. Cannabis is legal in the State of California however cannabis remains illegal under United States (“U.S.“) federal laws. The U.S. Department of Justice issued guidance in 2013 indicating that it will focus on certain enforcement priorities, outside of which it will generally not enforce federal prohibitions on cannabis in U.S. states that have authorized this conduct so long as the U.S. state has implemented a strong and effective regulatory program. This federal guidance is subject to change, rescission or alteration by other federal government policy pronouncements at any time. TOP’s business is conducted in a manner consistent with the State law of California and is in compliance with regulatory and licensing requirements applicable in the State of California. However, the readers should be aware that change in federal guidance on enforcement actions could adversely affect TOP’s ability to access private and public capital required in order to support continuing operations and its ability to operate in the U.S.

SOURCE Gabriella’s Kitchen

For further information: For investment inquiries, please contact Margot Micallef, Founder & CEO or Scott Koyich, Investor Relations at IR@gabriellas-kitchen.com or (800) 674-2239. For media inquiries, please contact Lana Rogers, Public Relations Consultant, at Lana@Lanarogerspr.com or (403) 519-7959

Related Links

https://gabriellas-kitchen.com

]]>
48North Cannabis Corp. Announces Transformational Acquisition and $10MM Private Placement https://mjshareholders.com/48north-cannabis-corp-announces-transformational-acquisition-and-10mm-private-placement/ Tue, 30 Oct 2018 16:36:27 +0000 http://www.cannabisfn.com/?p=1815302

TORONTO, Oct. 30, 2018 /CNW/ – 48North Cannabis Corp. (“48North” or the “Company”) (TSXV:NRTH) and 2599708 Ontario Inc. (“Good & Green”) have entered into a letter agreement that became binding on October 29, 2018, whereby 48North will acquire all of the issued and outstanding common shares of privately-held Good & Green in an all-share transaction valued at $18,000,000 (the “Acquisition”). 48North is also pleased to announce a $10,000,000 non-brokered private placement of units, including an approximately $7,000,000 lead order from a leading US-based private investment fund (the “Financing”).

With the Acquisition, 48North acquires a second Licensed Producer, as defined under the Cannabis Act, positioning itself as one of the largest and lowest cost producers of dried cannabis, cannabis oil, as well as a leader in next-generation cannabis infused products including cosmetics, topicals, beverages, and edibles.

The Acquisition provides 48North with a total expected 2019 production of at least 45,000 kilograms of high-quality dried cannabis, assuming receipt of applicable regulatory approvals. Good & Green’s cultivation and production facilities include an approximately 46,000 square foot indoor facility situated on five-acres of commercial land in Brantford, Ontario, as well as a 100-acre farm in Southwest Ontario. This significant production footprint includes 48North’s existing 2019 indoor expected production of 2,500 kilograms from DelShen Therapeutics Corp., the Company’s existing wholly-owned Licensed Producer.

“We are excited to acquire Good & Green, a company that shares our corporate values, strong management, and commitment to financial discipline,” said Alison Gordon, Chief Executive Officer of 48North. “With now two licensed facilities, we are optimally positioned for the next phase of cannabis legalization with extensive cultivation experience in large-scale, low-cost production.”

“48North continues to be a leader in developing cannabis brands and products with a future-focus that looks beyond flower and oil,” said Jeannette VanderMarel, co-founder and President of Good & Green. “We look forward to adding our expertise and significant low-cost organic production profile to further develop this dynamic and innovative vertically-integrated cannabis company.”

“We are pleased to be combining forces with 48North, a company that shares our commitment to the highest environmental, social and governance standards, to developing high-quality and consistent products and to achieving best-in-class financial performance,” said Daniel Goldberg, co-founder and Chief Executive Officer of Good & Green.

After closing of the Acquisition, Alison Gordon and Jeannette VanderMarel will become co-CEOs of 48North. Ms. VanderMarel will also join the Board of Directors of 48North. Daniel Goldberg will become Senior Advisor of 48North and will focus on strategy, business and corporate development, strategic partnerships, communications, as well as investor and government relations.

The Acquisition is expected to be completed through a three-cornered amalgamation whereby 48North will acquire 100% of Good & Green’s outstanding common shares from Good & Green’s shareholders in exchange for $18,000,000 of common shares (totalling 24,567,534 common shares) of 48North at a price of $0.73 per common share. 48North and Good & Green have agreed to a mutual break fee of $750,000. The Acquisition is expected to close on or before November 30, 2018 and is subject to, among other conditions, TSX Venture Exchange approval.

Acquisition Highlights

  • Further Strengthens a Values-Based Vertically-Integrated Cannabis Company: 48North is a vertically-integrated cannabis company focused on building strong brands and developing innovative, next-generation cannabis products. The Acquisition provides a significant increase in indoor and low-cost outdoor cannabis production, a substantial expansion into organic cannabis production, and further strengthens 48North’s brand portfolio.
  • Second Licensed Indoor Cultivation and Manufacturing Facility: The Acquisition provides an additional ~46,000 square feet of licensed indoor cultivation and manufacturing facility, situated on five-acres of land in Brantford, Ontario. This site has an initial production area of ~14,000 square feet with another ~25,500 square feet immediately available for additional indoor cultivation, pre and post-production, laboratory, large-scale extraction, as well as next-generation product, research, development and manufacturing. The Brantford indoor facility is expected to produce 2,500 kilograms of dried cannabis in 2019.
  • Low-Cost 100-Acre Outdoor Cultivation Site to Provide an Expected 40,000 Kilograms of Organic Dried Cannabis in 2019: The Acquisition provides 48North with a 100-acre organic farm situated in close proximity to the indoor Brantford, Ontario facility. This is in addition to 48North’s existing licensed facility in Kirkland Lake, Ontario. The farm is expected to produce at least 40,000 kilograms of dried cannabis in 2019. This includes outdoor grow with a targeted per gram production cost of $0.25, at a cost basis which is a fraction of the current, lowest-cost producer. Good & Green submitted a cultivation license application to Health Canada in relation to the farm in October 2018 and expects to receive that license by May 2019. The farm will provide 48North with organic, sun-grown cannabis and provides a significant first-mover advantage in the production of low-cost, next-generation, extract-based cannabis products.
  • Enhanced Management Team: Good & Green’s strong management team has best-in-class cultivation, facility development and construction, government relations, marketing, and branding experience, as well as M&A and corporate development capabilities. Good & Green’s senior team have all been involved in the MMPR/ACMPR/Cannabis Act since its inception. Together they have 12-plus years of experience and have developed over a million square feet of federally-licensed cannabis cultivation space.
  • Strong Access to and Immediate Availability of Capital: The concurrent Financing provides capital and liquidity to support the continued expansion of both companies, including the development of Good & Green’s 100-acre farm and large-scale extraction capabilities to significantly increase 2019 production and facilitate the rapid development of innovative, next-generation cannabis products.
  • Complementary Portfolio of Brands: The Acquisition provides 48North and Good & Green with the opportunity to leverage a combined portfolio of authentic, socially responsible, high-quality cannabis brands. The diversity and range of brands will increase access to multiple demographic segments through complimentary values-driven brands including 48North, Good & Green, Latitude and Mother & Clone.
  • Enhanced Liquidity and Continued Participation in Future Growth: Good & Green shareholders, through their ownership of 48North shares, will have the opportunity to participate in the growth of 48North and will benefit from the enhanced prospects of the combined company. The Acquisition will provide substantial infrastructure and operational support to accelerate the growth strategy of both companies with a focus on future product development and innovation.

Concurrent Non-Brokered Private Placement
Concurrent with the Acquisition, 48North is pleased to announce the Financing, for minimum gross proceeds of $10,000,000. In connection with the Financing, 48North is expected to issue Preferred Units and Common Units.

Each Preferred Unit will, subject to shareholder approval, be comprised of one Preferred Share and one quarter of one Preferred Share Purchase Warrant (each whole Preferred Share Purchase Warrant, a “Preferred Warrant”). In connection with issue of the Preferred Shares, the Company is expected to seek shareholder approval to permit the creation of the Preferred Shares at its upcoming Annual General Meeting, expected to be held on January 2, 2019 (the “AGM”).

The Preferred Shares will be convertible into Common Shares of the Company and will rank parri passu with the Common Shares in all respects, other than the holder’s right to redeem at par if certain provisions concerning confidentiality and restrictions against unlawful U.S. operations are breached by 48North. Additional information with respect to the Preferred Shares will be provided in the meeting materials to be delivered to shareholders of the Company in connection with the AGM.

Each Common Unit will be comprised of one Common Share and one quarter Common Share Purchase Warrant (each whole Common Share Purchase Warrant, a “Common Warrant”). Each full Common Warrant will entitle the holder to acquire an additional Common Share of 48North for a period of 12 months from the date of issue at a strike price of $1.15, provided that, the expiry of the warrants can be accelerated if the closing price of the company’s common shares on the TSX Venture Exchange (“TSXV”) is at least $1.50 for a minimum of 10 consecutive trading days and a notice of acceleration is provided in accordance with the terms of the warrant, may accelerate the expiry date to the warrants to a date 30 days after the date of the notice.

The Preferred Warrants will have the same terms as the Common Warrants but be exercisable for a Preferred Share instead of a Common Share.

Certain of the Units issued in the Financing may be subject to a four-month hold period under provincial securities laws in Canada and the TSXV policies and may be subject to additional resale restrictions based upon the jurisdiction in which the purchaser is resident.

The Financing is expected to close in tranches, with the Common Unit tranche of the Financing expected to close on or about November 30, 2018, and the Preferred Share tranche of the Financing expected to close in early January 2019.

The Acquisition is at arm’s length and definitive documentation is expected to be signed ahead of closing, scheduled for November 30, 2018.

About 48North Cannabis Corp.
48North Cannabis Corp. is a TSXV listed company who cultivates premium dried flower to create next-generation cannabis products for the health and wellness market. Assets include a cultivation, sales and extraction license by Health Canada,unique genetics sourced from MariPharm B.V. in the Netherlands, a large- scale, low-cost, sun-grown 100-acre outdoor farm; two modern indoor licensed cultivation and production facilities; and partnerships with leaders in cannabis, manufacturing and consumer packaged goods. 48North also has a growing portfolio of brands that include Latitude: a women’s cannabis platform (explorelatitude.com), Good & Green: a socially-responsible, organic cannabis brand (goodandgreen.com) and Mother & Clone: a rapid-acting sublingual cannabis nanospray (momandclone.com).

About Good & Green
Good & Green is a federally licensed, socially responsible, organic cannabis company co-founded by Jeannette VanderMarel (co-founder The Green Organic Dutchman) and Daniel Goldberg (formerly PharmaCan, Macquarie, CIBC, and National Bank). The company is focused on developing high quality, consistent, homogeneous organic cannabis and cannabis products. Good & Green operates from a 46,000 square foot indoor facility situated on five acres of land in Brantford, Ontario. Good & Green has also applied for a cultivation license for its 100-acre farm in southwest Ontario, which is capable of producing at least 40,000 kg of dried cannabis. The company anticipates beginning production on the farm in the early spring of 2019.

Good & Green’s Advisory Panel includes Trina Fraser (Partner, Brazeau Seller LLP), Steve Kroft (CEO, Conviron), Anita Wortzman (President, Farmers Edge), and Dr. Gillian Davidson (CEO, Wild Horse Consulting Ltd.).

DISCLAIMER & READER ADVISORY

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the parties’ current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. Forward looking statements in this news release include statements relating to the expected benefits of the Acquisition. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including the possibility that the Acquisition will not be completed, or that 48North may not derive the expected benefits from the Acquisition described in this news release. Additionally, this release contains forward-looking information relating to the Financing, including the timing and ability of the Company to obtain an outdoor cultivation license through Health Canada, close the Financing, if at all, the gross proceeds of the Financing, and the timing and ability of the Company to obtain all necessary approvals, including shareholder approval of the creation of the Preferred Shares. The business of the Company is subject to a number of material risks and uncertainties. Please refer to the Company’s SEDAR filings for further details. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include the Company being able to obtain the necessary corporate, regulatory and other third parties approvals, and licensing and other risks associated with the Cannabis Act. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

SOURCE 48North Cannabis Corp.
View original content: http://www.newswire.ca/en/releases/archive/October2018/30/c8690.html

please contact: Heidi Christensen Brown, 48North Investor Relations, christensenbrown@national.ca; David Hackett, Chief Financial Officer, 48North, IR@48nrth.com; Daniel Goldberg, CEO, Good & Green, info@goodandgreen.comCopyright CNW Group 2018

]]>
BLOCKStrain Addresses Cannabis Diversion & Inversion Challenges https://mjshareholders.com/blockstrain-addresses-cannabis-diversion-inversion-challenges/ Mon, 29 Oct 2018 16:11:44 +0000 http://www.cannabisfn.com/?p=1808860

Ryan Allway

October 29th, 2018

News, Press Releases, Top News


The U.S. cannabis industry is projected to reach $75 billion by 2030, according to Cowen & Co., driven by the legalization of medical and recreational cannabis across a growing number of states. At the same time, Deloitte believes Canada’s cannabis industry will reach C$22.6 billion within five years following the legalization of recreational cannabis on a national level—a move that made it the first G7 nation to address the problem.

In this article, we will take a look at some of the challenges facing consumers, businesses, and regulators within the cannabis industry and how companies like BLOCKStrain Technology Corp. (TSX-V: DNAX) (OTC: BKKSF) aim to address the issues head-on using innovative new technology.

Diversion vs. Inversion Issues

Lawmakers across North America are calling for strict regulatory oversight to prevent diversion—or the transfer of legal cannabis to the black market. Overproduction and high tax rates have encouraged some cultivators in the United States to risk their licenses and sell excess cannabis into the black market to recoup costs or generate excess profits. These activities not only enrich criminal enterprises, but could damage the industry’s credibility.

In Canada regulators have seen producers licensed under the Medical Marijuana Access Regulations abusing their license to produce very small amounts of cannabis, and instead produce massive quantities of cannabis and extracts bound for the black market.

For example, a medical cannabis grow operation was recently shut down near Toronto after it was discovered that personal medical marijuana licenses were being used to grow $6.5 million in illegal plants across 22 industrial greenhouses. These kinds of industrial-scale personal grows have become magnets for theft and violence, with a number of homicides linked to what would normally be considered legal businesses.

Inversion—or the sale of black market product in the legal market—has become an equally concerning problem. Black market product is untested and could contain pesticides, heavy metals, and other contaminants. Consumers that unknowingly purchase black market cannabis could be taking on significant health risks. Over time, these problems could lead to a crisis of confidence in the industry on the part of consumers.

How Seed-to-Sale Tracking Helps

Seed-to-sale tracking solutions can help address both diversion and inversion problems facing the legal cannabis industry. Under these schemes, individual plants are tagged with barcodes or identification tags that are used to track them through the supply chain. The closed-loop system helps prevent diversion from occurring, since regulators can easily check and see whether yields are abnormally low given a certain number of plants.

BLOCKStrain Technology Corp. (TSX-V: DNAX) (OTC: BKKSF) goes one step further with Genome-to-Sale™ tracking powered by an immutable blockchain-powered ledger. By utilizing a genetic based identification system and placing that information into a unique barcode, cannabis consumers, businesses, regulators, and even other software companies can quickly determine everything from potential contamination to the potency of each strain. Strain breeders at Licensed Producers can also ensure their intellectual property is protected when licensing strains.

The company began by partnering with licensed testing facilities and streamlining the lab process to reduce red tape. For each batch of products processed, a blockchain transaction is created, thus becoming a unique identifier that is used throughout the supply chain. Craft growers use the platform to protect the intellectual property of their unique strains, and now, licensed producers like WeedMD Inc. (TSX-V: WMD) have entered the fold.

Looking Ahead

Inversion and diversion are enormous problems facing the North American cannabis industry. If they’re not addressed, it could lead regulators to crack down on legal cannabis programs in the United States and hurt consumer confidence in product quality.

BLOCKStrain Technology Corp. (TSX-V: DNAX) (OTC: BKKSF) has developed an innovative solution to the problem and already onboarded several high-profile users. Investors may want to keep a close eye on the stock over the coming quarters as it rolls out the platform.

For more information, visit the company’s website or download their investor presentation.

Disclaimer 

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>